Heart failure with reduced ejection fraction has seen remarkable advances with multiple medical therapies that reduce mortality. Despite these breakthroughs, guideline-recommended medical therapy (GDMT) is underutilized. The reasons for suboptimal implementation are manifold but surmountable. These include gaps in clinician knowledge, patient reluctance to take chronic medications, clinical inertia, and, increasingly, GDMT affordability.
No takes yet. Share an insight, caveat, or question.
Sandhu et al. (2021) conducted a review in Heart failure with reduced ejection fraction. Guideline-directed medical therapy (GDMT) was evaluated. Guideline-directed medical therapy for heart failure with reduced ejection fraction remains underutilized due to affordability, clinical inertia, clinician knowledge gaps, and patient reluctance.
Synapse has enriched 5 related papers. Consider them for comparative context: